


Abstract

In a German-Dutch consortium the Cell Puncher Pro demonstrator has been developed and validated to enable the analysis of individual Circulating Tumor Cells (CTC) to guide cancer therapy. Personalized cancer treatment based on the tumor composition (proteins, DNA and RNA) will become the standard in the next ten years. This requires solutions to determine the tumor composition at multiple time points during the course of therapy. With the financial support of the INTERREG program, the consortium consisting out of 5 SME's, 3 University hospitals and the Technical University of Twente have developed and validated the Cell Puncher Pro platform till TRL-7. This Cell Puncher Pro platform will contribute to a more personalized cancer treatment. In 2022 this platform will come to the market for the first customers.

Development of disposables, hardware and software



Workflow: Processing lung and prostate cancer samples for personalized therapy



German-Dutch ecosystem

UKD Universitätsklinikum
Düsseldorf

micronit

IDpartners
DESIGN FOR INDUSTRY

KaneTronics



UKM
Universitätsklinikum
Münster

UNIVERSITY
OF TWENTE.



VYCAP

